CINECA IRIS Institutional Research Information System

CRUCITTA, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.489
EU - Europa 1.334
AS - Asia 673
AF - Africa 142
SA - Sud America 40
OC - Oceania 14
Totale 4.692
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.446
IT - Italia 682
CN - Cina 316
SG - Singapore 232
SE - Svezia 219
BG - Bulgaria 94
CI - Costa d'Avorio 92
DE - Germania 82
AT - Austria 68
GB - Regno Unito 62
CA - Canada 38
BR - Brasile 35
VN - Vietnam 34
SN - Senegal 28
TR - Turchia 27
FR - Francia 25
PL - Polonia 24
NL - Olanda 22
NG - Nigeria 18
FI - Finlandia 14
IN - India 14
HK - Hong Kong 12
AU - Australia 10
RU - Federazione Russa 10
ES - Italia 8
KR - Corea 8
ID - Indonesia 7
BE - Belgio 5
LT - Lituania 4
NZ - Nuova Zelanda 4
CH - Svizzera 3
IR - Iran 3
JP - Giappone 3
RO - Romania 3
TW - Taiwan 3
UZ - Uzbekistan 3
BO - Bolivia 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
MA - Marocco 2
MX - Messico 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AZ - Azerbaigian 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
LK - Sri Lanka 1
NO - Norvegia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
SA - Arabia Saudita 1
SV - El Salvador 1
TH - Thailandia 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 4.692
Salva come PNG Salva come JPEG
Città #
Santa Clara 310
Fairfield 262
Chandler 211
Woodbridge 164
Houston 157
Ashburn 145
Shanghai 141
Seattle 137
Pisa 115
Florence 98
Singapore 95
Sofia 94
Wilmington 94
Abidjan 92
New York 90
Boardman 88
Cambridge 84
Vienna 65
Serra 59
Princeton 56
Ann Arbor 55
Lawrence 48
Medford 38
Turin 38
London 37
Milan 36
Frankfurt am Main 35
Dakar 28
Beijing 27
Ottawa 26
Rome 26
Istanbul 24
San Diego 21
Warsaw 20
Ogden 19
Lagos 18
Los Angeles 17
Dong Ket 16
Dearborn 14
Cascina 13
Fuzhou 13
Livorno 13
Bremen 12
Hong Kong 12
Washington 12
Chiesina Uzzanese 11
Des Moines 11
Boulder 10
Marseille 10
Nuremberg 10
Quanzhou 10
Nanjing 9
Redwood City 9
Genoa 8
Lucca 8
Toronto 8
Naples 7
San Francisco 7
Guangzhou 6
Iowa City 6
San Giuliano Terme 6
Vicopisano 6
Columbus 5
Dallas 5
Helsinki 5
Redmond 5
Brussels 4
Changsha 4
Hebei 4
Hefei 4
Jakarta 4
Lappeenranta 4
Mazara del Vallo 4
Monza 4
Napoli 4
Seregno 4
Amsterdam 3
Bandung 3
Cagliari 3
Camaiore 3
Chengdu 3
Hyderabad 3
Jiaxing 3
Kilburn 3
Kunming 3
Munich 3
Norwalk 3
Novara 3
Pistoia 3
Pontedera 3
Prato 3
San Vito Chietino 3
Seoul 3
Verona 3
Wuhan 3
Zhengzhou 3
Anzio 2
Bangalore 2
Baoding 2
Bergamo 2
Totale 3.445
Salva come PNG Salva come JPEG
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 249
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 135
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 134
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 128
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 120
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 117
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 116
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 115
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 114
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients 113
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 113
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? 110
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 108
KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA 107
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 105
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management 104
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 101
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 101
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 99
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 99
CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats 96
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 93
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 92
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 89
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 88
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring 87
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients 86
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide 86
Circulating biomarkers of response to immunotherapy in cancer treatment 82
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 82
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA 80
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 79
ErbB in NSCLC as a molecular target: Current evidences and future directions 79
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 76
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs 72
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 67
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells 67
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone 64
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers 63
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 62
Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives 61
Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview 59
Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients 57
Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation 56
Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer 55
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 48
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 45
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC 41
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 41
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs 39
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients 38
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival 37
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours 37
Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics 35
Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies 34
A real-world application of liquid biopsy in metastatic colorectal cancer: The poseidon study 33
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 31
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 28
The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies 28
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients 22
β3-adREnoceptor Analysis in CORD Blood of Neonates (β3 RECORD): Study Protocol of a Pilot Clinical Investigation 21
TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma 20
Recurrent USP6 rearrangement in a subset of atypical myofibroblastic tumours of the soft tissues: low-grade myofibroblastic sarcoma or atypical/malignant nodular fasciitis? 17
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated Acute Myeloid Leukemia (AML) to guide treatment strategy 16
null 15
Totale 4.892
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.706
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.706
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020291 0 0 0 0 0 0 80 67 67 31 36 10
2020/2021353 18 20 6 37 24 10 65 12 65 16 32 48
2021/2022523 7 8 6 4 98 98 46 21 33 30 34 138
2022/20231.061 106 136 89 51 92 107 24 75 259 13 99 10
2023/2024809 53 66 123 43 67 147 43 28 20 46 84 89
2024/2025976 74 72 39 126 254 280 131 0 0 0 0 0
Totale 4.892